KR20180137918A - Composition for preventing and treating a cancer comprising curcuma zedoaria - Google Patents

Abstract

The present invention relates to an anticancer activity of an extract of Curcuma zedoaria. Specifically, the present invention relates to uses of an extract of Curcuma zedoaria as a composition for preventing or treating cancer, an anticancer sub-agent, and a food composition for preventing or ameliorating cancer, by confirming the effect of inducing apoptosis of cancer cells since the extract of Curcuma zedoaria is cytotoxic to cancer cells, increases intracellular ROS and induces ER-stress response.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing and treating cancers,

The present invention relates to an anticancer activity of an extract, and more particularly, to a killing effect of cancer cells due to ER-stress induction and ROS development in an extract.

The smallest unit that makes up the human body is called a cell. Normal cells divide by the intracellular regulating function, grow, die and disappear, and maintain the balance of the cell number. When a cell is damaged for some reason, it is treated and acts as a normal cell, or it self-destroys if it is not recovered. However, when the gene of a cell changes for various reasons, the cell is abnormally changed to incompletely mature, and the cell cycle is not regulated so that the cell division is continued, which is defined as cancer. Cancer is also characterized by its ability to invade the tissues and organs of the state and destroy them, as well as spread to other organs. The death rate due to cancer is the number one cause of death in Korea, and the number is increasing every year. Although there has been considerable progress in the medical treatment of certain cancers, the overall 5-year survival rate for all cancers has improved by only about 10% over the past 20 years. Cancer, or malignant tumors rapidly metastasize and grow in an uncontrolled manner, it is extremely difficult to detect and treat them on time. Among these, multiple myeloma is a multiple cancer of the whole body caused by abnormally proliferating plasma cell which produces and secretes antibody. It causes fracture, peripheral neuropathic pain, hypercalcemia, Monoclonal protein and production lead to kidney failure. The incidence of multiple myeloma and the mortality rate are increasing with the aging of multiple myeloma. However, since multiple myeloma is a rare disease that accounts for 1% of cancer diseases, the cost of health insurance is not guaranteed and the cost of patients is high. In addition, boterzomib, thalidomide, and lenalidomide are mainly used as anticancer drugs. However, The side effects of the drug remain a pending issue.

Currently, surgery, radiation therapy, and chemotherapy are used to treat cancer. Of these, chemotherapy refers to a method of treating cancer using an anticancer agent. Today, about 60 kinds of various anticancer drugs are used. Recently, as knowledge of cancer development and characteristics of cancer cells is well known, researches on the development of new anticancer drugs are being actively carried out. Many patients in cancer chemotherapy suffer from the side effects of anticancer drugs, especially because of the toxicity of anticancer drugs. The anticancer substances used in clinical use have effects such as side effects and anticancer drug resistance, such as failure to treat the cancer cells as well as normal cells as well as repeated administration. A new type of anticancer drug is being studied to overcome the side effects of existing anticancer drugs caused by the diversity of the cancer itself and the variety of pathogenic mechanisms.

On the other hand, ER stress refers to the infiltration of immature proteins into the endoplasmic reticulum beyond the ability of the endoplasmic reticulum to be treated by a physiological or pathological environment, or depletion of calcium in the endoplasmic reticulum. Specifically, in the ER, the UPR (Unfenced Protein Response) mechanism is initiated while misfolding proteins and overexpressing proteins bind to the chaperone Bip / Grp78 (ER transmembrane receptor protein) located in the lumen of the ER. It is not active at normal time, but is separated from the receptor by binding to the over-folded protein and the over-expressed protein. Then, PERK (protein kinase RNA-like endoplasmic reticulum kinase) is autophosphorylated in the cytoplasm, (Negative feedbeck) of the elf2 factor, the binding initiator of mRNA, to regulate phosphorylation. In this process, the G1 phase of the cell cycle is inhibited and the most important CHOP (CCAAT / -enhancer-binding protein homologous protein) is expressed in ER stress. Followed by mitochondrial damage leading to cleavage of PARP associated with apoptosis. The most important CHOP produces reactive oxygen species (ROS).

Avoiding apoptosis is a typical feature of malignant cells, and cell resistance to apoptosis is an important clinical problem (Jia et al. , 2012; Lopez-Beltran et al. , 2007). Accordingly, the inventors of the present invention focused on the fact that cancer is similar to the concept of 癰 疽 and cumulative (聚 疽) as the concept of Oriental medicine while trying to find a natural product with a low side effect that can prevent and cure cancer, The present inventors have completed the present invention by confirming that the outbreak, which is a kind of phytoplankton, induces ER stress, thereby inducing intracellular ROS and inducing apoptosis, thereby exhibiting an anticancer effect against multiple myeloma.

In the present invention, it has been confirmed that the extract of the present invention is cytotoxic to cancer cells and induces ROS and ER stress in multiple myeloma cells to induce apoptosis. Thus, the extract can be used as a composition for preventing or treating cancer, As a food composition for preventing or ameliorating osteoporosis.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising an ascorbic acid extract as an active ingredient.

In addition, the present invention provides an anticancer adjuvant comprising an extract as an active ingredient.

In addition, the present invention provides a food composition for preventing or ameliorating cancer containing an ascorbic acid extract.

According to the present invention, the extract has an effect of eliminating cancer cells by inducing apoptosis of multiple myeloma cells, increasing intracellular ROS, inducing ER-stress reaction and inducing apoptosis.

FIG. 1 is a graph showing the cell survival rate of multiple myeloma cell line U937 by treatment with an extract.
FIG. 2 is a graph showing the degree of expression of apoptosis-related protein and ER stress-inducing protein in the multiple myeloma cell line U937 by treatment with an extract.
FIG. 3 is a chart for confirming the degree of ROS production in the multiple myeloma cell line U937 by treatment with an extract.

Hereinafter, the present invention will be described in detail with reference to embodiments of the present invention. It should be understood, however, that the invention is not limited thereto and that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined by the appended claims and their equivalents. .

In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating cancer comprising curcuma zedoaria extract as an active ingredient.

In one embodiment, the extract may be extracted with water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, more preferably ethanol.

The term " extract " used in the present invention means a preparation which is obtained by squeezing a herbal medicine with an appropriate leaching solution and concentrating the liquid by evaporating the leaching solution. The extract is not limited thereto, but may be a diluent or concentrate of the extract, A dried product obtained by drying the extract, a controlled preparation thereof, or a purified product thereof. The extract can be prepared by a general extraction method, separation and purification methods known in the art. The extraction method may be, but not limited to, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction.

In the present invention, the extract may be prepared by extracting with an extraction solvent or extracting with an extraction solvent, followed by fractionation with a fraction solvent. The organic solvent may be an alcohol having 1 to 4 carbon atoms, a polar solvent such as ethyl acetate or acetone, a solvent such as hexane or dichloro, or an organic solvent such as dichloromethane, Methane, or a mixed solvent thereof may be used. Further, water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof may be preferably used, and more preferably ethanol can be used. In one embodiment of the present invention, the extract was extracted with 100% ethanol as the solvent, and then concentrated under reduced pressure to prepare an extract.

In one embodiment, the cancer is selected from the group consisting of: colorectal cancer, breast cancer, cervical cancer, cervical cancer, ovarian cancer, prostate cancer, brain tumor, head and neck carcinoma, melanoma, myeloma, leukemia, lymphoma, stomach cancer, pancreatic cancer, Renal cell carcinoma, kidney cell carcinoma, renal pelvic carcinoma, bone cancer, skin cancer, head cancer, endometrial carcinoma, endometrial carcinoma, vulvar carcinoma, Hodgkin's disease, bladder cancer, kidney cancer, Cancer of the central nervous system (CNS), primary CNS lymphoma, spinal cord tumor, cervical cancer, endometrial carcinoma, endometrial carcinoma, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, Brain giant glioma, and pituitary adenoma. It is more preferable that the myeloma is multiple myeloma.

In one embodiment, the extract extract may be included at a concentration of 10-200 μg / ml, more preferably 10-100 μg / ml.

In one embodiment, the prevention or treatment of cancer can be accomplished by increasing cell death and ROS due to endoplasmic reticulum (ER) stress.

In one embodiment of the present invention, it was confirmed that apoptotic cell death caused by multiple extract treatment was increased. In order to confirm this anticancer activity mechanism, expression of CHOP most important in ER stress and ROS and apoptosis related PARP (FIG. 2), confirming that CHOP expression was increased and PARP cleavage was increased and myosomal ROS was increased (FIG. 2). Thus, the extract of the present invention induced ER-stress and ROS, , Which is an antitumor activity.

As used herein, the term " apoptosis " is also referred to as apoptosis or apoptosis, and is a kind of programmed cell death (PCD), which is characterized by abnormal cells, damaged cells, aged It is a mechanism that allows cells to maintain their overall physical health by killing themselves and killing themselves.

In the present invention, the term " prevention " means any action which inhibits or delays the development, spread and recurrence of cancer by the administration of the pharmaceutical composition according to the present invention, and " treatment " Suspicion of cancer and all the behaviors that alleviate or ameliorate symptoms of the onset individuals.

The term " treatment " as used herein refers to any action that improves or alleviates the death or cancer of a cancer cell by administering a composition comprising the outbreak of the present invention. Those skilled in the art will be able to ascertain the precise criteria of the disease for which the composition of the present invention is effective by referring to the data presented by the Korean Medical Association, will be.

The term " therapeutically effective amount " used in connection with the active ingredient in the present invention means the amount of a pharmaceutically acceptable salt of the extract of the invention which is effective for preventing or treating the target disease, The amount can vary depending on a number of factors, such as the mode of administration, the site of administration, the condition of the patient, and the like. Therefore, when used in the human body, the dosage should be determined in consideration of safety and efficacy. It is also possible to estimate the amount used in humans from the effective amount determined through animal experiments. Such considerations in determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman ' s Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; And E.W. Martin ed., Remington ' s Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term " pharmaceutically effective amount " means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, Factors well known in the art and other medical disciplines including health status, type of cancer, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and rate of release, duration of treatment, ≪ / RTI > The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiply. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect in a minimal amount without side effects, which can be easily determined by those skilled in the art.

The pharmaceutical compositions of the present invention may include carriers, diluents, excipients, or a combination of two or more thereof commonly used in biological formulations. As used herein, the term " pharmaceutically acceptable " means that the composition is free of toxicity to cells or humans exposed to the composition. The carrier is not particularly limited as long as the composition is suitable for in vivo delivery, for example, Merck Index, 13th ed., Merck & Inc. A buffered saline solution, a buffer solution, a dextrose solution, a maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used, and if necessary, an antioxidant, a buffer, Conventional additives may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into main dosage forms such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990) in a suitable manner in the art.

The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, Wherein the starch is selected from the group consisting of lactose, mannitol, sugar, arabic gum, pregelatinized starch, cornstarch, powdered cellulose, hydroxypropyl cellulose, opaques, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, Calcium, white sugar, dextrose, sorbitol and talc may be used. The pharmaceutically acceptable additive according to the present invention is preferably included in the composition in an amount of 0.1 part by weight to 90 parts by weight, but is not limited thereto.

The pharmaceutical composition of the present invention may further comprise a known anticancer agent in addition to the extract as an active ingredient and may be used in combination with other known treatments for the treatment of these diseases. Other treatments include, but are not limited to, chemotherapy, radiation therapy, hormone therapy, bone marrow transplantation, stem cell replacement therapy, other biological therapies, immunotherapy, and the like.

Examples of anticancer agents that can be included in the pharmaceutical composition of the present invention include DNA alkylating agents such as mechloethamine, chlorambucil, phenylalanine, mustard, cyclophosphate, Cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin cisplatin and carboplatin; The anticancer antibiotics include dactinomycin (actinomycin D), doxorubicin (adriamycin), daunorubicin, idarubicin, mitoxantrone, Plicamycin, mitomycin C, and bleomycin; And plant alkaloids such as vincristine, vinblastine, paclitaxel, docetaxel, etoposide, teniposide, topotecan, And iridotecan, but are not limited thereto.

In one aspect, the invention relates to a method of preventing or treating cancer, comprising administering an extract to an individual in need thereof.

The term " individual " used in the present invention means a monkey, a horse, a sheep, a pig, a chicken, a turkey, a quail, a cat, a dog, a mouse, a rat, a rabbit Refers to all animals including guinea pigs, and the diseases can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to an individual. The pharmaceutical composition of the present invention can be administered in parallel with existing therapeutic agents.

The term " administering " as used herein means providing a predetermined substance to a patient in any appropriate manner, and may be administered orally or parenterally (for example, by intravenous, subcutaneous, The dosage may vary depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease. Examples of the liquid preparation for oral administration of the composition of the present invention include suspensions, solutions, emulsions, syrups, and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, Etc. may be included together. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. The pharmaceutical composition of the present invention may be administered by any device capable of moving the active substance to the target cell. The preferred modes of administration and formulations are intravenous, subcutaneous, intradermal, intramuscular, and drip injections. The injectable solution may be a non-aqueous solvent such as an aqueous solvent such as a physiological saline solution or a ring gel solution, a vegetable oil, a higher fatty acid ester (e.g., oleic acid), an alcohol (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.) (For example, ascorbic acid, sodium hydrogen sulfite, sodium pyrophosphate, BHA, tocopherol, EDTA and the like), an emulsifier, a buffer for pH control, a microbial growth inhibitor And a pharmaceutical carrier such as a preservative (e.g., mercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).

In one aspect, the invention ahchul (Curcuma zedoaria ) extract as an active ingredient.

In one aspect, the invention ahchul (Curcuma The present invention relates to a food composition for preventing or ameliorating a cancer containing a zedoaria extract.

When the composition of the present invention is used as a food composition, the extract can be used as it is or can be used in combination with other food or food ingredients, and can be suitably used according to ordinary methods. The composition may contain a food-acceptable food-aid additive in addition to the active ingredient, and the amount of the active ingredient to be mixed may be suitably determined according to the intended use (prevention, health or therapeutic treatment).

As used herein, the term " food-aid additive " refers to a component that can be added to foods in a supplementary manner, and is appropriately selected and used by those skilled in the art as added to produce health functional foods of each formulation. Examples of food-aid additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, , a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, and a carbonating agent used in a carbonated drink. However, the types of the food auxiliary additives of the present invention are not limited by these examples.

A health functional food may be included in the food composition of the present invention. The term " health functional food " as used in the present invention refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. Here, 'functional' refers to the structure and function of the human body to obtain nutritional effects and obtain useful effects for health use such as physiological action. The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components which are usually added in the conventional technical fields. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The composition for food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has the advantage that there is no side effect that may occur when a drug is used for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to enhance the effectiveness of anticancer drugs.

There is no limitation on the kind of health food to which the composition of the present invention can be used. In addition, the composition comprising the extract of the present invention as an active ingredient may be prepared by mixing a suitable auxiliary ingredient, which may be contained in a health functional food, with a known additive according to the selection of a person skilled in the art. Examples of foods that can be added include dairy products, such as meat, sausage, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Vitamin complex, and the like, and can be prepared by adding to the juice, tea, jelly, and juice prepared from the extract of the present invention as a main component.

Since the extract of the present invention uses natural plants as a raw material, it can be used safely in pharmaceutical composition and health functional food because it can be less harmful than general synthetic compound even when it is used as a pharmaceutical composition or a food composition.

The present invention will be described in more detail with reference to the following examples. However, the following examples are only for the purpose of illustrating the present invention, and thus the present invention is not limited thereto.

Example  One. Out ( Curcuma zedoaria ) Preparation of extract

The extracts were extracted with 100% ethanol and concentrated under reduced pressure to prepare an extract of ethanol.

Experimental Example  1. Identification of cytotoxicity of extracts from multiple myeloma

To confirm the anticancer activity against the multiple myeloma of the outpatient extract prepared in Example 1, 50 쨉 l of U937 cell line (Korean Cell Line Bank), which is a multiple myeloma cell line, was dispensed into a 96 well plate at a rate of 2 x 10 ⁴ cells / In RPMI medium supplemented with 10% inactivated fetal bovine serum and 1% penicillin-streptomycin, And cultured in a 5% CO ₂ incubator (MCO-15AC, Sanyo, Osaka, Japan) at 37 ° C. 50 μl, 100 μl, 150 μl, and 200 μl / ml of the extract prepared in Example 1 were added to the cultured cell line U937, and the cells were incubated for one day. Cells incubated in the dark state were treated with 10 [mu] l of EZ-Cytox reagent (DoGen) and incubated for 30 minutes to 4 hours, and cell viability was confirmed at 450 nm absorbance of the microplate reader (Bio-rad Model 680).

As a result, it was shown that the extracts were toxic to multiple myeloma in a concentration-dependent manner, and that multiple myeloma was killed without significant difference in concentration after 100 μg / ml (FIG. 1).

Experimental Example 2. Determination of apoptosis inducing effect of multiple myeloma by extracts

In order to examine the effect of the extract prepared in Example 1 on apoptosis in multiple myeloma, induction of DNA damage and induction of ER stress with PARP (Poly ADP ribose polymerase), which is known to be cleaved in progression of apoptosis, The expression level of CHOP (C / EBP homologous protein) used as a marker of apoptosis was confirmed by Western blot analysis. Specifically, U937 cell line, a multiple myeloma cell line, was treated with 0, 50 and 100 μg / ml of the extract prepared in Example 1, respectively, and incubated in a 5% CO ₂ incubator at 37 ° C. for 24 hours. Cells were then harvested, washed with PBS and resuspended in cell-disrupted buffer RIPA (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM NaEDTA, 1 mM EGTA, 1% NP-40, 1% sodium pyrpphophate, 1 mM beta-glycerophosphate , 1 mM Na ₃ VO ₄ and 1 [mu] g / ml leupeptin (Cell signaling)) was added thereto and the cells were disrupted at 4 [deg.] C for 30 minutes. Cell lysates were centrifuged at 15,520 × g for 20 min to remove cell membrane components and the proteins were quantified using RC DC ™ Protein Assay Kit II (Bio-Rad, USA) 0, 50 and 100 [mu] g / ml treated groups). Proteins were denatured by adding 5x loading dies to the prepared protein samples and heating to 95 ° C for 5 minutes. Thereafter, the sample was loaded on an 8 to 10% SDS-PAGE gel and electrophoresed at 90 to 100 V for 1 hour and 30 minutes to 3 hours. Proteins separated from the gel were incubated at 200 mA to 300 mA for 1 hour to 4 hours And transferred to the membrane. Protein-transferred membranes were blocked with TBST (tris buffered saline, pH 7.5) solution containing 5% skim milk for 2 hours at room temperature, followed by primary antibody anti-PARP (Cell signaling) and anti-CHOP (Cell signaling) Were each diluted 1: 500 and reacted with the blocked membrane at 4 ° C for 1 hour to overnight. The membranes were washed three times with TBST, and anti-rabbit IgG conjugated with horseradish peroxidase was diluted 1: 2,000, reacted with membrane at room temperature for 1 hour, and washed three times with TBST. The washed membrane was reacted with a chemiluminescent reagent for 1 to 3 minutes and photographed on a film to visualize the protein band.

As a result, it was found that the cleavage of PARP was increased and the expression of CHOP was increased depending on the concentration of the extract, and the cell death and ER-stress were enhanced by the extract of the extract. Dependent manner (FIG. 2).

Experimental Example  3. In multiple myeloma Out  Determination of active oxygen inducing effect of extract

To examine the effect of the extract prepared in Example 1 on multiple myeloma, 4 × 10 ⁵ U937 cell lines, which are multiple myeloma cell lines, were washed with PBS, and then DCFDA Cellular Reactive Oxygen Species Detection Assay kit (abcam) 20 mM, incubated at 37 캜 for 30 minutes in a dark state, and then washed again with PBS. Subsequently, 2 x 10 ⁴ cells (50 μl) were dispensed on a 96-well plate, and 50 μl of the overexpressed extract prepared in Example 1 was treated at 0, 50 and 100 μg / ml, respectively, Lt; / RTI > After that, the absorbance was measured at 485/535 nm using a microplate reader.

As a result, it was found that treatment with 50 μg / ml or 100 μg / ml of the outgrowth increased ROS production in multiple myeloma cells (FIG. 3).

Claims (8)

Curcuma zedoaria ) extract as an active ingredient. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the extract is extracted with water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof. The method of claim 1, wherein the cancer is selected from the group consisting of colon cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, brain tumor, head and neck carcinoma, melanoma, myeloma, leukemia, lymphoma, gastric cancer, lung cancer, Renal cancer, renal cell carcinoma, renal pelvic carcinoma, bone cancer, skin cancer, head cancer, endometrial carcinoma, endometrial carcinoma, vulvar carcinoma, Hodgkin's disease, bladder cancer, kidney cancer, , Central nervous system (CNS) tumor, primary CNS lymphoma, spinal cord tumor, soft tissue sarcoma, soft tissue sarcoma, soft tissue sarcoma, urethral cancer, penile cancer, endocrine cancer, thyroid cancer, , Brain stem glioma, and pituitary adenoma. ≪ Desc / Clms Page number 19 > The pharmaceutical composition according to claim 1, wherein the cancer is multiple myeloma. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the extract has a concentration of 10 to 200 占 퐂 / ml. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the prevention or treatment of cancer is accomplished by an apoptosis and ROS increase due to an endoplasmic reticulum (ER) stress of cancer cells. An anticancer adjuvant containing an extract as an active ingredient. A food composition for preventing or ameliorating cancer containing an extract.

Images